Last updated: 2026-10-15 03:56:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Mustang Bio, Inc. (MBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.37, with a market capitalisation of $3.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.37 to $1.69. This page covers its latest market performance, valuation, price trends and company information.
$3.12M | |
$0.39 | |
$10,012.50 | |
$0.37 | |
$0.38 | |
159.01K | |
29.93K | |
-- | |
$1.69 | |
$0.37 | |
-- | |
-- |
Mustang Bio, Inc. (MBIO) last closed at $0.38 as of 2026-10-14 23:51:00, unchanged from the previous close of $0.38.
During the latest regular trading session, MBIO traded between $0.37 and $10,012.50, with a volume of 159.01K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Mustang Bio, Inc. (MBIO) moved from $0.46 to $0.37, representing a decline of 19.37% ($0.09).
The stock traded between $0.37 and $0.47 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 52.09 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.2%
MBIO is currently trading at $0.37, placing it 0.2% of the way from its 52-week low of $0.37 to its 52-week high of $1.69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Mustang Bio, Inc. (MBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.